<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01613898</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-09-7393-HC-CTIL</org_study_id>
    <nct_id>NCT01613898</nct_id>
  </id_info>
  <brief_title>Evaluation of Carotid IMT and Atherogenic Risk Factors in Patients With Cerebrotendinous Xanthomatosis</brief_title>
  <acronym>CTX</acronym>
  <official_title>Evaluation of Carotid IMT and Atherogenic Risk Factors in Patients With Cerebrotendinous Xanthomatosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the proposed study is to evaluate the risk for cardiovascular disease and&#xD;
      'atherogenic' features of the serum in CTX and to determine preclinical atherosclerosis. The&#xD;
      study will include an extensive assessment of lipoprotein profile and carotid artery&#xD;
      intima-media thickness (cIMT) measurement.&#xD;
&#xD;
      Lipid and lipoprotein profiles will include novel tests such as direct measurements of&#xD;
      apolipoprotein A1,B,C2,C3 plasma levels, lipoprotein (a) levels, highly sensitive C-reactive&#xD;
      protein levels and PLAC test that measures the levels of lipoprotein-associated phospholipase&#xD;
      A2-a vascular-specific inflammatory enzyme implicated in the formation of atherosclerosis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Protocol 09-2009 EVALUATION OF CAROTID IMT AND ATHEROGENIC RISK FACTORS IN PATIENTS WITH&#xD;
      CEREBROTENDINOUS XANTHOMATOSIS&#xD;
&#xD;
      ABSTRACT Cerebrotendinous xanthomatosis (CTX) is a rare disease characterized by xanthomatous&#xD;
      lesions in many tissues, mainly in the brain. Mutation in the gene of sterol&#xD;
      27-hydroxylase-an enzyme in bile acid synthesis causes CTX. The impaired synthesis of&#xD;
      chenodeoxycholic acid from cholesterol results in elevated plasma and bile cholestanol.&#xD;
&#xD;
      The natural course of CTX is progressive neurologic deterioration from childhood through&#xD;
      adulthood leading to diffuse damage of the central and peripheral nervous systems and&#xD;
      eventually to death.&#xD;
&#xD;
      Cardiovascular involvement in CTX is probably high: different clinical manifestations of&#xD;
      cardiovascular disease (CVD) were reported in 10.4% of patients with CTX. The precise&#xD;
      mechanism of the atherosclerosis in CTX is unknown and may be related to cholestanol&#xD;
      accumulation in the vascular subendothelial space.&#xD;
&#xD;
      Abnormalities in the lipoprotein profile were not described in the literature, and&#xD;
      cholesterol levels are within normal limits in CTX. Extensive evaluation for CVD risk factors&#xD;
      in the CTX patient group have not been conducted apart from a small number of publications.&#xD;
&#xD;
      The aim of the proposed study is to evaluate the risk for cardiovascular disease and&#xD;
      'atherogenic' features of the serum in CTX and to determine preclinical atherosclerosis. The&#xD;
      study will include an extensive assessment of lipoprotein profile and carotid artery&#xD;
      intima-media thickness (cIMT) measurement.&#xD;
&#xD;
      Lipid and lipoprotein profiles will include novel tests such as direct measurements of&#xD;
      apolipoprotein A1,B,C2,C3 plasma levels, lipoprotein (a) levels, highly sensitive C-reactive&#xD;
      protein levels and PLAC test that measures the levels of lipoprotein-associated phospholipase&#xD;
      A2-a vascular-specific inflammatory enzyme implicated in the formation of atherosclerosis.&#xD;
&#xD;
      This would be the first attempt to conduct such an extensive evaluation in the CTX patients&#xD;
      group.&#xD;
&#xD;
      Research Plan:&#xD;
&#xD;
      Study Design and Methods&#xD;
&#xD;
      Subjects The study population will constitute of all 17 CTX diagnosed patients that will be&#xD;
      recruited from the CTX outpatient clinic at the Parkinson's disease and movement disorders&#xD;
      Clinic in the Sagol Neuroscience Center, at the Chaim Sheba Medical Center. Patients will be&#xD;
      contacted by phone and by mail and be invited to participate.&#xD;
&#xD;
      Control group will consist of age and gender matched healthy individuals. All patients or&#xD;
      their legal guardians will sign an informed consent.&#xD;
&#xD;
      Detailed Plan of the Study&#xD;
&#xD;
      All study participants will undergo an evaluation that will include one clinic visit :&#xD;
&#xD;
      Visit 1&#xD;
&#xD;
        -  A detailed medical history, including demographic data, past medical history, smoking&#xD;
           history, use of medications, and family history of dyslipidemia and atherosclerotic&#xD;
           cardiovascular disease.&#xD;
&#xD;
        -  Physical examination including height and weight measurements, blood pressure, BMI,&#xD;
           waist and hip circumference.&#xD;
&#xD;
        -  Blood samples&#xD;
&#xD;
             1. Fasting Lipid profile:&#xD;
&#xD;
                Total cholesterol, HDL-cholesterol, direct LDL-cholesterol and Triglycerides (TG)&#xD;
&#xD;
             2. Apolipoprotein profile:&#xD;
&#xD;
             1. apolipoprotein A1&#xD;
&#xD;
             2. apolipoprotein B&#xD;
&#xD;
             3. apolipoprotein C2&#xD;
&#xD;
             4. apolipoprotein C3&#xD;
&#xD;
           c. lipoprotein (a) [Lp(a)] d. C-Reactive Protein -hsCRP e. Lipoprotein-associated&#xD;
           Phospholipase A2 (Lp-PLA2) f. Apo E genotyping g. Plasma cholestanol level h. Fasting&#xD;
           plasma glucose and Insulin&#xD;
&#xD;
        -  12 lead electrocardiogram (ECG)&#xD;
&#xD;
        -  cIMT assessment.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
        -  Laboratory studies&#xD;
&#xD;
        -  Blood samples will be taken after an overnight fast&#xD;
&#xD;
        -  Total cholesterol, HDL-cholesterol and TG in plasma will be determined by colorimetric&#xD;
           enzymatic procedures (Olympus, Ireland).&#xD;
&#xD;
        -  Apolipoprotein A1, B, C2, C3 and Lp(a) serum concentrations will be determined by the&#xD;
           immuno-turbidimetric procedure . (Olympus, Ireland).&#xD;
&#xD;
        -  Direct LDL- will be determined by enzymatic color test. (Olympus, Ireland).&#xD;
&#xD;
        -  HsCRP- will be determined by turbidimetric immunoassay(Olympus, Ireland)&#xD;
&#xD;
        -  Lp-PLA2 (PLAC® Test) - The PLAC Test measures Lp-PLA2 (lipoprotein-associated&#xD;
           phospholipase A2), a vascular-specific inflammatory enzyme implicated in the formation&#xD;
           of rupture-prone plaque. Turbidimetric Immunoassay for the Quantitative Determination of&#xD;
           Lp-PLA2 in Human Plasma (diaDexus, Inc. CA .USA) The Olympus AU 400 autoanalyzer will be&#xD;
           used for all the above-mentioned measurements.&#xD;
&#xD;
        -  Apo E genotyping- Apo E genotypes of genomic DNA from blood will be determined by a&#xD;
           single nucleotide primer extension Elisa assay. (Pronto Diagnostics, Tel Aviv, Israel )&#xD;
&#xD;
        -  Plasma cholestanol level- will be measured by high-performance liquid chromatography&#xD;
           with ultraviolet detection (Halperin et al , ref 10 )&#xD;
&#xD;
        -  Glucose -will be measured by the glucose oxidase method (Olympus AU2700, Hamburg,&#xD;
           Germany).&#xD;
&#xD;
        -  Insulin- will be measured by a chemiluminiscent immunometric method (Immulite 2000,&#xD;
           Diagnostic Products Corporation, Los Angeles, CA).&#xD;
&#xD;
        -  ECG-12 lead electrocardiogram will be done. (Mac 1100,GE medical systems, Germany)&#xD;
&#xD;
      Carotid artery Intima-media thickness : Patients will undergo a color-coded duplex&#xD;
      examination of neck vessels using a 10MHz linear array ultrasound (Hitachi medical&#xD;
      corporation, Tokyo, Japan). IMT will be evaluated on the common carotid arteries (CCAs) over&#xD;
      ≈1.5 cm proximal to the flow divider, according to standardized guidelines. In brief, IMT&#xD;
      will be measured at the thickest plaque-free point on the near and far walls with a specially&#xD;
      designed computer program. CCA wall thickness will be defined as the mean of the maximum wall&#xD;
      thickness of the near and far walls bilaterally. Ultrasound images of the distal 1 cm of the&#xD;
      far wall of each common carotid artery will be obtained and compared with values from a&#xD;
      normative data set (age and sex matched). Mean CIMT values from the far walls of the right&#xD;
      and left common carotid arteries will be reported&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2010</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Predisposition of CTX patients for pro-atherogenic features as evaluated by lipid and lipoproteins plasma profiles, and blood chemical assessment. Preclinical atherosclerosis in CTX patients as determined by Carotid artery Intima-media thickness 1.</measure>
    <time_frame>3 years</time_frame>
    <description>The predisposition of the serum of CTX patients to be pro-atherogenic will be evaluated by detailed lipid and lipoproteins plasma profiles, and blood chemical assessment of specific inflammatory pro-atherogenenic features.&#xD;
IMT Presence of preclinical atherosclerosis will be determined by Carotid artery Intima-media thickness as a marker of risk for cardiovascular disease.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">17</enrollment>
  <condition>Cerebrotendinous Xanthomatosis (CTX)</condition>
  <arm_group>
    <arm_group_label>CTX Group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood tests</intervention_name>
    <description>Blood tests</description>
    <arm_group_label>CTX Group</arm_group_label>
    <other_name>CTX Group</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Lipid and lipoprotein profiles&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The study population will constitute of all 17 CTX diagnosed patients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non CTX patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hofit Cohen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Bert W. Strassburger Lipid Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Bert W. Strassburger Lipid Center</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>tamar luvish, BSN</last_name>
      <phone>972-35303492</phone>
      <email>tamar.luvish@sheba.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Hofit Cohen, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>May 22, 2012</study_first_submitted>
  <study_first_submitted_qc>June 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2012</study_first_posted>
  <last_update_submitted>June 6, 2012</last_update_submitted>
  <last_update_submitted_qc>June 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cerebrotendinous xanthomatosis (CTX),</keyword>
  <keyword>lipoprotein,atherosclerosis,</keyword>
  <keyword>carotid artery intima-media thickness (cIMT).</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Xanthomatosis, Cerebrotendinous</mesh_term>
    <mesh_term>Xanthomatosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

